

**Inhibitory effect of *Ocotea quixos* (Lam.) Kosterm. and *Piper aduncum* L. essential oils from Ecuador on West Nile virus infection.**

Journal:	<i>Plant Biosystems</i>
Manuscript ID	TPLB-2018-0017.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	07-Apr-2018
Complete List of Authors:	Radice, Matteo; Universidad Estatal Amazonica Pietrantoni, Agostina; Istituto Superiore di Sanita Guerrini, Alessandra; Universita degli Studi di Ferrara Tacchini, Massimo; Universita degli Studi di Ferrara Dipartimento di Scienze della Vita e Biotecnologie Sacchetti, Gianni; Universita degli Studi di Ferrara Chiurato, Matteo; Universita degli Studi di Ferrara Venturi, Giulietta; Istituto Superiore di Sanita Fortuna, Claudia; Istituto Superiore di Sanita,
Keywords:	<i>Ocotea quixos</i> , <i>Piper aduncum</i> , essential oil, West Nile virus, antiviral activity, Ecuadorian Amazon Region

SCHOLARONE™  
Manuscripts

1 **Inhibitory effect of *Ocotea quixos* (Lam.) Kosterm. and *Piper aduncum***  
2 **L. essential oils from Ecuador on West Nile virus infection.**

3 Matteo Radice<sup>1</sup>, Agostina Pietrantonì<sup>2</sup>, Alessandra Guerrini<sup>3</sup>, Massimo  
4 Tacchini<sup>3</sup>, Gianni Sacchetti<sup>3</sup>, Matteo Chiurato<sup>3</sup>, Giulietta Venturi<sup>4</sup>, Claudia  
5 Fortuna<sup>4\*</sup>

6 <sup>1</sup>*Universidad Estatal Amazónica, Puyo, Ecuador*

7 <sup>2</sup>*National Center for Innovative Technologies in Public Health, Istituto Superiore di*  
8 *Sanità, Rome, Italy*

9 <sup>3</sup>*Department of Life Sciences and Biotechnology (SVeB), University of Ferrara,*  
10 *Malborghetto di Boara, Ferrara, Italy*

11 <sup>4</sup>*Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy*

12  
13 \*Corresponding author: Dr. Claudia Fortuna

14 E-mail address: [claudia.fortuna@iss.it](mailto:claudia.fortuna@iss.it)

15  
16 Matteo Radice, Universidad Estatal Amazónica, Km 2 ½ Via Puyo-Tena, Puyo,  
17 Ecuador, [mradice@uea.edu.ec](mailto:mradice@uea.edu.ec), 00593 032-888-118 / 032-889-118

18 Agostina Pietrantonì, National Center for Innovative Technologies in Public Health,  
19 Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy,  
20 [agostina.pietrantonì@iss.it](mailto:agostina.pietrantonì@iss.it), +390649902092

21  
22 Alessandra Guerrini, Department of Life Sciences and Biotechnology (SVeB),  
23 University of Ferrara, P.le Chiappini, 3 44123 Malborghetto di Boara, Ferrara, Italy,  
24 [alessandra.guerrini@unife.it](mailto:alessandra.guerrini@unife.it), +39 0532 29 3774 +39 0532 29 3781

25  
26 Massimo Tacchini, Department of Life Sciences and Biotechnology (SVeB), University  
27 of Ferrara, P.le Chiappini, 3 44123 Malborghetto di Boara, Ferrara, Italy,  
28 [massimo.tacchini@unife.it](mailto:massimo.tacchini@unife.it), +39 0532 29 3774 +39 0532 29 3781

29  
30 Gianni Sacchetti, Department of Life Sciences and Biotechnology (SVeB), University  
31 of Ferrara, P.le Chiappini, 3 44123 Malborghetto di Boara, Ferrara, Italy, [scg@unife.it](mailto:scg@unife.it),  
32 +39 0532 29 3774 +39 0532 29 3781

33 Matteo Chiurato, Department of Life Sciences and Biotechnology (SVEB), University  
34 of Ferrara, P.le Chiappini, 3 44123 Malborghetto di Boara, Ferrara, Italy,  
35 [matteo.chiurato@gmail.com](mailto:matteo.chiurato@gmail.com), +39 0532 29 3774 +39 0532 29 3781

36 Giulietta Venturi, Department of Infectious Diseases, Istituto Superiore di Sanità, Viale  
37 Regina Elena 299, 00161 Rome, Italy, [giulietta.venturi@iss.it](mailto:giulietta.venturi@iss.it), +390649902663

38 Claudia Fortuna, Department of Infectious Diseases, Istituto Superiore di Sanità, Viale  
39 Regina Elena 299, 00161 Rome, Italy, [claudia.fortuna@iss.it](mailto:claudia.fortuna@iss.it), +390649902663

40

41

42

#### 43 **Abstract**

44 West Nile virus (WNV) is a mosquito-borne flavivirus responsible of  
45 neuroinvasive manifestations. Natural products are well-known for their  
46 biological activities and pharmaceutical application. In this study the  
47 inhibitory effects of essential oils (EOs) of *Ocotea quixos* (Lam.) Kosterm.  
48 and *Piper aduncum* L. on WNV replication were investigated.

49 WNV was incubated with EOs before adsorption on Vero cells, viral  
50 replication was carried out in the absence or presence of EO. Cells were  
51 exposed to EO before the adsorption of untreated-virus. GC-MS and GC-  
52 FID were used for chemical characterization of EOs.

53 Cell protection from infection was observed for both EOs. *P. aduncum* EO  
54 was characterized by dillapiole as main compound (48.21%) and *O. quixos*  
55 EO by 1,8-cineole (39.15%).

56 ~~*O. quixos* and *P. aduncum* should be considered for further investigations,~~  
57 ~~such as the study of molecular and cellular mechanisms of action and *in*~~  
58 ~~*vivo* evaluation for the development of a compound against WNV.~~

59 Further investigations, such as the study of molecular and cellular  
60 mechanisms of action and *in vivo* evaluation, should be performed on  
61 these essential oils to derive new potential drugs against WNV.

62

63           **Keywords:** *Ocotea quixos*, *Piper aduncum*, essential oil, West Nile virus,  
64           antiviral activity, Ecuadorian Amazon Region.

## 69    **Introduction**

70    West Nile virus (WNV) is a mosquito-borne flavivirus, family *Flaviviridae*, widely  
71    distributed throughout Africa, the Middle East, Asia, Southern Europe, Australia and  
72    the Americas. The virus was originally isolated from Uganda in 1937. WNV caused  
73    epidemic outbreaks in Asia, Europe and Australia and, in the 1999, it was introduced  
74    into the United States where it became endemic (Saxena et al. 2017). While birds serve  
75    as amplifier hosts, mosquitoes of the *Culex* genus function as vectors. Humans and  
76    horses are dead-end hosts (David and Abraham 2016). WNV causes asymptomatic  
77    infections in 80% of cases, while 19% of patients develop flu-like illnesses. In less than  
78    1% of the symptomatic individuals, virus entry into the central nervous system (CNS)  
79    results in neuroinvasive manifestations, such as meningitis, encephalitis, poliomyelitis,  
80    and death (Gubler 2007). Despite the important impact of WNV infection-associated  
81    diseases on human health, there are currently no available human vaccines or specific  
82    antiviral therapies ~~for this disease~~. To date, only a West Nile vaccine is available for  
83    horses. Natural products are widely used all over the world as treatment for many  
84    diseases and deeper investigations are justified from several studies (Newman and  
85    Cragg 2007; Bhalla et al. 2013; Atanasov et al. 2015). A recent study demonstrated the  
86    antiviral potential of different polyphenols present in plants and natural products, such  
87    as wine and tea, against WNV, by affecting the attachment and entry steps of the virus  
88    life-cycle (Vázquez-Calvo et al. 2017). Further studies on the antiviral potential of

1  
2  
3 89 natural compounds against WNV are not reported to date. Moreover, Ecuador belongs  
4  
5 90 to a selected group of 17 countries defined “Megadiverse” due to its impressive  
6  
7 91 biological diversity (Mittermeier et al. 1999; Sierra et al. 2002), which is an important  
8  
9 92 source of bioactive compounds. EOs from Ecuadorian Amazon region (EAR) have been  
10  
11 93 investigated in the last decades in order to deeper their biological activities (Bruni et al.  
12  
13 94 2004; Tognolini et al. 2006; Sacchetti et al. 2006; Scalvenzi et al. 2007; Guerrini et al.  
14  
15 95 2014).

16  
17  
18 96 To our knowledge, studies evaluating antiviral effect of *O. quixos* (Lam.) Kosterm.  
19  
20 97 (Lauraceae) and *P. aduncum* L. (Piperaceae) EOs against WNV have not been reported.  
21  
22 98 *O. quixos* (Lam.) Kosterm belongs to the Lauraceae family. It is traditionally used as  
23  
24 99 ingredient for infusions and beverages or as a flavoring for foods (Naranjo 1981;  
25  
26 100 Friedman et al. 1993). Although few studies have been carried out on the biological  
27  
28 101 properties of *O. quixos*, *in vivo* and *in vitro* investigations on this plant highlighted  
29  
30 102 significant anti-inflammatory activity of its EO (Ballabeni et al. 2009).

31  
32  
33 103 *P. aduncum*, from Piperaceae family, is well-known in folk medicine for the  
34  
35 104 antimicrobial and insecticide activities and for the treatment of dysentery and wound  
36  
37 105 healing (Durant-Archibold et al. 2018).

38  
39 106 Many studies have been performed on *P. aduncum* demonstrating efficacy of EO as  
40  
41 107 insect repellent (Mamood et al. 2017) and ethanolic extract as antiviral plant-derived  
42  
43 108 product (Lohézic-Le Dévéhat et al. 2002). Moreover the importance of the *P. aduncum*  
44  
45 109 EO has been demonstrated also against *P. falciparum* indicating that this EO could be a  
46  
47 110 promising antimalarial agent (Monzote et al. 2017). In an effort to identify antiviral  
48  
49 111 therapies effective against WNV, in this study potential antiviral effect of *quixos* and *P.*  
50  
51 112 *aduncum* EOs were tested *in vitro*.

52  
53  
54  
55 113 **Methods**

## 114 **Material and Methods**

### 115 **Plant material**

116 Fresh leaves of *O. quixos* (~~Canela amazónica~~) and *P. aduncum* (~~Matiko~~) plants were  
117 collected from a wild population in the Amazonian region of Pastaza (Ecuador) in June  
118 2016. Species authentication were certified by Dr. David Neill and voucher specimens  
119 from each plant were deposited at the Herbarium ECUAMZ of the Amazonian State  
120 University (UEA) in Ecuador (voucher specimen: Neill 18070B, Scalvenzi 18070C).

### 122 **Isolation of EOs**

123 The EOs were obtained by hydrodistillation in a stainless steel distiller equipped with a  
124 Clevenger apparatus, performing three distinct distillations for 4 h. All samples for each  
125 EO were gathered, dried over anhydrous sodium sulphate and stored in sealed amber  
126 vials at 4°C.

### 128 **Gas-chromatographic analysis of EOs**

129 The compound identification was realized by **GC-MS** analysis and the quantification of  
130 individual components was performed by **GC-FID**, calculating the relative peak average  
131 area of three separated injections. The instrument used for quantitative determination  
132 was a ThermoQuest GC-Trace gas-chromatograph equipped with a FID detector and a  
133 Varian FactorFour VF-5ms poly-5% phenyl-95%-dimethylsiloxane column (i.d., 0.25  
134 mm; length, 30 m; film thickness, 0.15 µm). Operating conditions were as follows:  
135 injector temperature 300°C, FID temperature 300°C, carrier (Helium) flow rate 1  
136 **mL/min** and split ratio 1:50. The initial oven temperature was 55°C and then raised to

1  
2  
3 137 100°C at a rate of 1°C/min, then raised to 250°C at a rate of 5°C/min and then kept  
4  
5 138 constant at 250°C for 15 min. One microliter for each replicate was dissolved in CH<sub>2</sub>Cl<sub>2</sub>  
6  
7 139 (Sigma-Aldrich) and injected. The EOs percentage composition was computed by the  
8  
9 140 normalization method from the GC peak areas, without using correction factors. The  
10  
11 141 compound identification of EOs were performed by a Varian GC-3800 gas  
12  
13 142 chromatograph equipped with a Varian MS-4000 mass spectrometer using electron  
14  
15 143 impact and hooked to NIST library. The conditions were the same described for GC  
16  
17 144 analysis and also the same column was used. The mass spectrometry conditions were as  
18  
19 145 follows: ionization voltage, 70 eV; emission current, 10 µAmp; scan rate, 1 scan/s; mass  
20  
21 146 range, 29-400 Da; trap temperature, 150°C, transfer line temperature, 300°C. The EO  
22  
23 147 compounds were characterized by comparing their linear retention indices and the MS  
24  
25 148 fragmentation pattern with those of other known EOs, with pure compounds and by  
26  
27 149 matching the MS fragmentations patterns and linear retention indices with the above  
28  
29 150 mentioned mass spectra libraries and with those in the literature (Adams 2007). The  
30  
31 151 linear retention index of each component was determined adding a C<sub>8</sub>-C<sub>32</sub> n-alkanes  
32  
33 152 (Sigma-Aldrich) to the EO before injecting in the GC-MS equipment and analyzed  
34  
35 153 under the same conditions reported above (Guerrini et al. 2014)[14].  
36  
37  
38  
39  
40  
41  
42

154

#### 155 **Preparation of mother solution for biological assays**

156 An aliquot of dimethylsulfoxide (DMSO; Sigma–Aldrich) was added to the stock  
157 solution of each EO in order to obtain a 84mg/mL concentration range. Serial dilutions  
158 of the DMSO/EO solution were made with virus dilution buffer for the infection and  
159 with MEM maintenance medium for maintaining.

1  
2  
3 160  
4  
56 161 **Cell culture and virus**  
7

8  
9 162 African green monkey kidney (Vero) cells were grown at 37° C in a humidified  
10  
11 163 atmosphere, with 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM; Lonza,  
12  
13 164 Milan, Italy) supplemented with 10% inactivated fetal calf serum (FCS, Flow  
14  
15 165 Laboratories, Irvine, UK.), 2 mM glutamine, 2% non-essential amino acids (Gibco,  
16  
17 166 Paisley, UK), penicillin (100 IU/mL), and streptomycin (100 µg/mL). WNV strain,  
18  
19 167 lineage 1, isolated from a patient during the WNV outbreak occurred in Sardinia Region  
20  
21 168 in 2011 (Magurano et al. 2012) [H5] was used for the study. For virus production  
22  
23 169 monolayers of Vero cells in 75-cm<sup>2</sup> tissue culture flasks were infected with WNV. After  
24  
25 170 5 days at 37° C, infected cells were harvested with freeze-and-thaw cycle, and cellular  
26  
27 171 debris was removed with low-speed centrifugation, and virus titer was measured by  
28  
29 172 standard plaque assay. The virus was stored at -80° C until used.  
30  
31  
32

33  
34 173  
3536 174 **Plaque assay**  
37

38  
39 175 WNV titer was determined by plaque assays in Vero cells growing in 24-well plates.  
40  
41 176 Briefly, serial tenfold dilutions of the viral suspension were added (0.1 mL/well) in  
42  
43 177 duplicate. After infection, the cells were incubated for 1 h at 37°C. Subsequently,  
44  
45 178 Tragacanth gum powder (SIGMA cat. G1128-100G) supplemented 1:1 with DMEM  
46  
47 179 medium with 5% inactivated FBS, 2 mM glutamine, 2% non-essential amino acids,  
48  
49 180 penicillin (100 IU/mL), and streptomycin (100 µg/mL) was added, and the plate was  
50  
51 181 incubated for 5 days at 37° C. The viral plaques were visualized by 1% crystal violet  
52  
53 182 solution (Fortuna et al. 2015). The titer was estimated by counting the number of  
54  
55  
56  
57



1  
2  
3 183 plaques observed in each well and expressed as plaque-formation unit per milliliter  
4  
5 184 (p.f.u./mL) (viral titer:  $6,93 \times 10^6$  p.f.u./mL).  
6  
7

8 185  
9

### 10 11 186 **Cytotoxicity assay** 12

13  
14 187 A cytotoxicity test was performed for all EOs. Each EO was diluted 1:10 in DMSO and  
15  
16 188 subsequent several dilutions were made in MEM medium. Vero cell monolayers were  
17  
18 189 put in contact with the mixture of MEM medium plus oil and maintained at 37° C with  
19  
20 190 5% CO<sub>2</sub>. The cells were monitored daily to check the EO toxicity. After 24 h, the  
21  
22 191 following parameters were evaluated: cell morphology and viability (determined by  
23  
24 192 neutral red staining) were examined by light microscopy and cell proliferation was  
25  
26 193 evaluated quantitatively by microscopic counts after dispersion into individual cells  
27  
28 194 with trypsin. EO dilutions that did not affect any of these parameters were considered as  
29  
30 195 non-cytotoxic concentrations and utilized for antiviral assays. For neutral red staining  
31  
32 196 the 50% cytotoxic concentration (CC<sub>50</sub>) was defined as the concentration that reduces  
33  
34 197 the optical density (OD) of treated cells to 50% with respect to untreated cells  
35  
36 198 (Pietrantonì et al. 2015).  
37  
38  
39

40 199

### 41 42 43 200 **Dose-Response Assay** 44

45  
46 201 The antiviral activity of *O. quixos* and *P. aduncum* EOs was assayed by neutral red  
47  
48 202 assay. Briefly, in 96-well culture plate, monolayer cultures of Vero cells were incubated  
49  
50 203 with different concentrations of *O. quixos* and *P. aduncum* starting from 2.6 µg/mL  
51  
52 204 during the virus attachment step (1h 4° C). As viral inoculum was utilized WNV at a  
53  
54 205 multiplicity of infection (m.o.i.) of 0.1 p.f.u./cell. After adsorption, Vero cells were  
55  
56  
57  
58  
59  
60

1  
2  
3 206 rinsed thoroughly and incubated with the same concentrations of EO. The cells were  
4  
5 207 maintained at 37° C in 5% CO<sub>2</sub>. The cytopathic effect (CPE) induced by WNV was  
6  
7 208 measured 72 hours after infection by the neutral red uptake assay. Briefly, treated and  
8  
9 209 untreated cells were stained for 3 h at 37° C with neutral red (10 mg/mL), thereafter  
10  
11 210 cells were washed with Phosphate Buffered Saline (PBS) and fixed with 4%  
12  
13 211 formaldehyde, 10% CaCl<sub>2</sub>. The uptaken dye was extracted by 1% acetic acid in 50%  
14  
15 212 ethanol and the optical density was measured at 540 nm in a spectrophotometer  
16  
17 213 (Pietrantonio et al. 2015). Results were expressed as percentage of cell viability with  
18  
19 214 untreated infected control cultures. The concentration that reduced the absorbance of  
20  
21 215 infected cells to 50% when compared to cell and virus controls was considered the  
22  
23 216 effective concentration (EC<sub>50</sub>). The EC<sub>50</sub> was calculated according to the following  
24  
25 217 equation:  $[(A - B) / (C - B) \times 100]$ , where A is the control sample absorbance, B is the  
26  
27 218 cell control absorbance, and C is the virus control absorbance. The selectivity index (SI)  
28  
29 219 was calculated using the CC<sub>50</sub> and EC<sub>50</sub> data and applying the formula  $SI = CC_{50}/EC_{50}$ .  
30  
31  
32  
33  
34  
35

### 36 221 **Antiviral activity**

37  
38  
39 222 The antiviral activity of the EOs was measured using the neutral red assay as already  
40  
41 223 described. The antiviral assays were performed at 24 h after seeding, using confluent  
42  
43 224 Vero cell monolayers cultured in 96-well plates. EOs and components were always used  
44  
45 225 at the non-cytotoxic concentration as follows (33.6, 16.8, 2.1, 1 µg/mL). Cells without  
46  
47 226 the EO were used as a control. The EOs were included in different time points as it  
48  
49 227 follows:  
50  
51  
52

53 228 i. To evaluate the presence of virucidal activity, direct inactivation of WNV by the  
54  
55 229 extracts was tested. Viral inoculum was mixed with varying concentrations of the EO  
56  
57  
58  
59  
60

1  
2  
3 230 incubated at 37°C in 5% CO<sub>2</sub> for 1 h. After that, viral inoculum was used to infect  
4  
5 231 monolayer cultures of Vero cells, at a m.o.i. of 0.1 p.f.u./cell. After incubation at 37° C  
6  
7 232 in 5% CO<sub>2</sub> for 1 h, the cells were washed and DMEM maintenance medium was added  
8  
9 233 and the cells were maintained at 37° C in 5% CO<sub>2</sub>.

10  
11  
12 234 ii. Cell monolayers were pre-treated 1h at 37° C with EO prior to inoculation with virus  
13  
14 235 by adding the EO at varying concentrations. After pre-treatment, the EO was removed  
15  
16 236 and cells were infected with virus at a m.o.i. of 0.1 p.f.u./cell and incubated at 37° C in  
17  
18 237 5% CO<sub>2</sub> for 1h. Then MEM maintenance medium was added and the cells were  
19  
20 238 maintained at 37° C in 5% CO<sub>2</sub>.

21  
22  
23  
24 239 iii. Experiments were also performed to determine the viral inhibitory effect of the  
25  
26 240 selected EOs during the adsorption step. Vero cells grown in 96-well plates were  
27  
28 241 infected in triplicate with 0.1 p.f.u./cell of virus and EO at concentration described  
29  
30 242 above.

31  
32  
33 243 For all the treatments the neutralized assay procedure was performed 72 h later,  
34  
35 244 according to the protocol described in cell viability assay (Pietrantonì et al. 2015).

36  
37  
38 245

### 39 40 41 246 **Statistical analysis**

42  
43  
44 247 The experiments were performed in triplicate. Relative standard deviations and  
45  
46 248 statistical significance (Student's t test;  $p \leq 0.05$ ) were calculated using software  
47  
48 249 STATISTICA 6.0 (StatSoft Italia srl).

49  
50  
51 250

### 52 53 251 **Results**

#### 54 55 252 **Chemical composition of EOs**

1  
2  
3 253 ~~The yield of distillation for *O. quixos* EO was 0.13±0.01% (w/v). The main component~~  
4  
5 254 ~~(Table 1) was represented by 1,8 cineole (39.15%), followed in less amount by  $\alpha$ -~~  
6  
7 255 ~~terpineol (7.65%), sabinene (6.46%),  $\alpha$  pinene (6.27%), p-cymene (6.12%), E-~~  
8  
9 256 ~~caryophyllene (4.73%), terpinen 4-ol (4.22%). Monoterpenes represented the main~~  
10  
11 257 ~~fraction of EO. Methyl cinnamate, a characteristic phenylpropanoid of floral calice EO~~  
12  
13 258 ~~(Bruni et al 2004), was a minor compound in EO obtained from leaves (1.53%). For *P.*~~  
14  
15 259 ~~*aduncum* EO, the yield was 0.16±0.01% (w/v). The phenylpropanoid dillapiole~~  
16  
17 260 ~~(48.21%), trans-ocimene (7.53%) and E-caryophyllene (4.80%) were the main~~  
18  
19 261 ~~compounds.~~  
20  
21  
22  
23  
24

### 25 263 **Cytotoxicity of EOs**

26  
27  
28 264 ~~A neutral red assay was used to determine the cytotoxicity effect of *O. quixos* and *P.*~~  
29  
30 265 ~~*aduncum* on Vero-cells in which the half-maximal cytotoxic concentration (CC50) value~~  
31  
32 266 ~~of each compound was calculated. Results illustrate a cytotoxic value of CC50 = 163~~  
33  
34 267  ~~$\mu\text{g/mL}$  for *P. aduncum* compared to *O. quixos* with CC50 = 840  $\mu\text{g/ml}$ . Treated cells~~  
35  
36 268 ~~with vehicle control, 1% DMSO did not show any cytotoxicity against Vero-cells.~~  
37  
38  
39

### 40 269 41 42 43 270 **Dose-Response Assay**

44  
45  
46 271 ~~In order to evaluate the effect of *O. quixos* and *P. aduncum* on viral replication, Vero~~  
47  
48 272 ~~cells were infected with WNV at 0.1 m.o.i. p.f.u./cell and exposed to various two-folds~~  
49  
50 273 ~~concentrations of EO starting from 2.6  $\mu\text{g/ml}$  for 72 h post-infection (p.i.).~~  
51  
52 274 ~~Results are presented in Fig-1 as percentage of cell viability and represent the average of~~  
53  
54 275 ~~three independent experiments. As showed in the figure both EOs were able to inhibit~~  
55  
56  
57  
58  
59  
60

1  
2  
3 276 viral replication but *O. quixos* was more effective at concentration of 268 and 134,4  
4  
5 277  $\mu\text{g/ml}$  respect *P. aduncum* that showed a viral inhibition similar for all concentration.  
6  
7 278 The 50% effective concentration (EC50) for *O. quixos* was 372  $\mu\text{g/ml}$  whit a selectivity  
8  
9 279 index (SI) of 2.2 as showed on (Table 2).

10  
11  
12 280

### 13 14 281 **Antiviral activity of *O. quixos* on WNV**

15  
16 282 In order to better investigate the inhibitory effects of *O. quixos* on WNV, EO was added  
17  
18 283 at different stages during viral infection. As showed on Fig 2 (A), pre-treatment of virus  
19  
20 284 with *O. quixos* showed relevant virucidal activity at concentrations of 33.6  $\mu\text{g/ml}$  and  
21  
22 285 16.8  $\mu\text{g/ml}$ . The EO was also effective at these concentrations when host cells were pre-  
23  
24 286 treated with drugs prior to infection, showing a percentage of cell vitality of 60% (Fig 2  
25  
26 287 (B)). Same results were obtained when *O. quixos* EO at concentration of 33.6  $\mu\text{g/ml}$  and  
27  
28 288 16.8  $\mu\text{g/ml}$  was present during the adsorption step (Fig 2 (C)). We, therefore, observed  
29  
30 289 similar inhibition effect on viral replication in all three conditions studied, when the EO  
31  
32 290 was used at the concentrations of 33.6  $\mu\text{g/ml}$  and 16.8  $\mu\text{g/ml}$ , with a percentage of cell  
33  
34 291 viability around 60%. No relevant inhibition was observed when the WNV was pre-  
35  
36 292 treated with EO at the concentrations of 2.1  $\mu\text{g/ml}$  and 1  $\mu\text{g/ml}$ , for all conditions used  
37  
38 293 (Fig 2 (A,B,C)).

39  
40  
41  
42 294

### 43 44 295 **Antiviral activity of *P. aduncum* on WNV**

45  
46 296 As showed on Fig 3 (A) antiviral activity of the *P. aduncum* was most pronounced  
47  
48 297 when viruses were treated before inoculation showing a percentage of cell viability of  
49  
50 298 79% at the concentrations of 33.6  $\mu\text{g/ml}$ , 88% at 16.8  $\mu\text{g/ml}$ , 87% and 78% at 2.1 and 1  
51  
52 299  $\mu\text{g/ml}$ , respectively. When cells were incubated with EO only 1  $\mu\text{g/ml}$  showed a small  
53  
54 300 protection (68% of cell viability) while no relevant antiviral activity was showed by the

1  
2  
3 301 ~~other concentrations (Fig 3(B)). When the EO was added during infection, the results~~  
4  
5 302 ~~showed an antiviral activity at all the concentrations with a percentage of cell viability~~  
6  
7 303 ~~of around 68% at 1 µg/ml (Fig 3 (C)).~~  
8

9 304

## 11 305 **Discussion and conclusion**

13 306 ~~Viral diseases are still a major problem for human health worldwide. Although natural~~  
14  
15 307 ~~products have inherently high chemical diversity, plant based products or bioactive pure~~  
16  
17 308 ~~compounds obtained from EOs may be a new source of antiviral drugs but a few~~  
18  
19 309 ~~number of studies focus on this research field. So far, only a limited number of drugs~~  
20  
21 310 ~~are effective against many of these viruses, which has prompted research into finding~~  
22  
23 311 ~~new antiviral lead molecules (Li et al. 2013, Elizaquível et al. 2013, Tanu and Harper~~  
24  
25 312 ~~2016, Schnitzler et al. 2007, Astani et al. 2010, Lohéziec-Le Dévéhat et al. 2002,~~  
26  
27 313 ~~Ocazonez et al. 2010, Swamy et al. 2016). *P. aduncum* EO has been investigated by~~  
28  
29 314 ~~several authors mainly focusing chemical characterization, antimicrobial, insecticidal,~~  
30  
31 315 ~~larvicidal and anti protozoic (Guerrini et al. 2009, Bernuci et al. 2016, Oliveira et al.~~  
32  
33 316 ~~2013, Villamizar et al. 2017, Ling A et al. 2009, Monzote et al. 2017), but no data are~~  
34  
35 317 ~~available regarding antiviral activity. Also *O. quixos* EO was characterized and tested~~  
36  
37 318 ~~for its antimicrobial, antiplatelet and antithrombotic activity (Sacchetti et al. 2006,~~  
38  
39 319 ~~Naranjo 1981, Rolli et al. 2014, Tognolini et al. 2006, Ballabeni et al. 2007); from our~~  
40  
41 320 ~~knowledge no antiviral activities test were performed until now. The limited efficacy of~~  
42  
43 321 ~~the current treatment of WNV infection enhances the need for novel therapies that~~  
44  
45 322 ~~include substances with innovative viral targets and/or mechanisms of action. Our study~~  
46  
47 323 ~~has been performed to analyse the potential capacity of *O. quixos* and *P. aduncum* EOs,~~  
48  
49 324 ~~collected in the Ecuadorian Amazon, to reduce the WNV replication in infected cells.~~  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 325 ~~The chemical composition of leaf *O. quixos* EO, showing 1,8-cineole (39.15%) as main~~  
4  
5 326 ~~component, cinnamate derivatives and E-caryophyllene among minor compounds, did~~  
6  
7 327 ~~not reflect our previously results (Sacchetti et al. 2006), where E-caryophyllene,~~  
8  
9 328 ~~einnamyl acetate and other derivatives were the characteristic molecules. The yield was~~  
10  
11 329 ~~instead comparable with our previous results. However, it should be noted that the~~  
12  
13 330 ~~variation of chemical composition for this EO has not yet been studied extensively. *P.*~~  
14  
15 331 ~~*aduncum* EO showed an overlapping composition to our previously data (Guerrini et al.~~  
16  
17 332 ~~2009), with small quantitative differences regarding minor compounds: furthermore,~~  
18  
19 333 ~~germaerene D (3.05%) was not detected in the previous studies. *P. aduncum* EO have~~  
20  
21 334 ~~been largely studied in the last two decades and the formation of two chemotypes by~~  
22  
23 335 ~~different biosynthetic routes has been evidenced. In fact, according to our data, Maia et~~  
24  
25 336 ~~al. (1998), Ciccio and Ballesterro (1997), Fazolin et al. (2007), De Almeida et al. (2009)~~  
26  
27 337 ~~isolated EOs from leaves of *P. aduncum* in different localities of Amazonian region and~~  
28  
29 338 ~~determined that dillapiole, formed by the shikimate pathway, was the main compound~~  
30  
31 339 ~~with a variability from 31.5% to 97.3%. The study of *P. aduncum* cultivation in~~  
32  
33 340 ~~Western Amazonian region confirmed dillapiole as major component (Silva et al. 2014).~~  
34  
35 341 ~~If the leaves were instead collected from species in Atlantic Forest, and Northeastern~~  
36  
37 342 ~~and Southeastern Brazil, terpene compounds such as (E)-nerolidol and linalool were~~  
38  
39 343 ~~detected as main components (De Almeida et al. 2009, De Oliveira et al. 2006,~~  
40  
41 344 ~~Navickiene et al. 2006). The yield of dillapiole chemotype EO in literature ranged from~~  
42  
43 345 ~~0.35% to 4.0% (Guerrini et al. 2009, Fazolin et al. 2007, De Almeida et al. 2009, Silva~~  
44  
45 346 ~~et al. 2014, Rali et al. 2007), our results instead showed a lower level (0.16%)~~  
46  
47 347  
48  
49  
50  
51  
52 348 ~~EOs were tested for their cytotoxicity on Vero cells, prior to the determination of their~~  
53  
54 349 ~~inhibitory effect against WNV. *P. aduncum* resulted relatively more toxic than *O.*~~  
55  
56  
57  
58  
59  
60

1  
2  
3 350 ~~*quixos*. The potential antiviral effect of different EOs was determined against WNV on~~  
4  
5 351 ~~Vero cells in vitro and both EOs tested exhibited a reduction of infectivity at non-~~  
6  
7 352 ~~cytotoxic concentration.~~  
8  
9 353 ~~High antiviral activity was observed for selected EOs when WNV was incubated with~~  
10  
11 354 ~~this substances prior host cell infection (virucidal activities). WNV is an enveloped~~  
12  
13 355 ~~virus and the results of our study highlighted that both *O. quixos* and *P. aduncum* show~~  
14  
15 356 ~~virucidal activity.~~  
16  
17 357 ~~Experiments aimed to assess the antiviral activity of EOs have been most frequently~~  
18  
19 358 ~~conducted on viruses of the herpes group, enveloped viruses (Novak 2011). Schnitzler~~  
20  
21 359 ~~et al. (2007) demonstrated a virucidal effect of peppermint oil, when herpes simplex~~  
22  
23 360 ~~virus was mixed with the essential oil prior to inoculation. The application of tea tree~~  
24  
25 361 ~~oil, the EO of *Melaleuca alternifolia*, for the treatment of recurrent herpes labialis has~~  
26  
27 362 ~~been recently reported (Carson et al. 2001, Schuhmacher et al. 2003). Accordingly, a~~  
28  
29 363 ~~virus lacking of envelope, like adenovirus, was not affected by eucalyptus EO (Cemelli~~  
30  
31 364 ~~et al. 2008). Therefore our results suggest that *O. quixos* and *P. aduncum* could directly~~  
32  
33 365 ~~inactivate WNV and might interfere with virion envelope structures or mask viral~~  
34  
35 366 ~~structures which are necessary for adsorption or entry into host cells.~~  
36  
37 367 ~~In this study, experiments were also performed to determine the viral inhibitory effect~~  
38  
39 368 ~~treating the cells with EOs before adsorption. This different approach was important to~~  
40  
41 369 ~~better investigate on mechanisms of antiviral action of the EOs. In our study, *O. quixos*~~  
42  
43 370 ~~showed a protection of the cells from viral infection unlike *P. aduncum*. These findings~~  
44  
45 371 ~~would suggest an ability of *O. quixos* to inhibit viral replication by interfering with the~~  
46  
47 372 ~~virus binding to the cells. *P. aduncum* didn't result protective when added to the cells~~  
48  
49 373 ~~before inoculum. In this case we might, in some ways, assume that the oil does not act~~  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 374 ~~by competing with the virus for binding to the cell, and that part of its activity relies on~~  
4  
5 375 ~~direct inactivation of the viral particles after virus adsorption.~~

6  
7 376 ~~For *O. quixos* we observed a good and similar protection from WNV infection adding~~  
8  
9 377 ~~the EO to the DMEM medium during the intracellular replication period, up to an EO~~  
10  
11 378 ~~concentration of 16.8 µg/ml. These results suggest that *O. quixos* could act directly on~~  
12  
13 379 ~~WNV virus and might interfere with virion envelope structures or mask viral structures,~~  
14  
15 380 ~~which are necessary for adsorption or entry into host cells. Thus different mechanisms~~  
16  
17 381 ~~of antiviral activity of different EOs and compounds seem to be present.~~

18  
19 382 ~~All together, these results support the potential use of EOs *in toto* from medicinal plants~~  
20  
21 383 ~~as agents for the treatment of viral infections. The effectiveness of the EOs from~~  
22  
23 384 ~~Amazonia against the viruses tested was variable, but their virucidal properties against~~  
24  
25 385 ~~these viruses suggest the application of this type of natural products as disinfectants or~~  
26  
27 386 ~~topical medicaments.~~

28  
29 387 ~~Previous studies with EOs from eucalyptus, tea tree and thyme (Astani et al. 2010),~~  
30  
31 388 ~~have shown the direct inactivating action of EOs and their components on virion~~  
32  
33 389 ~~infectivity (HSV-1), with the exception of 1,8 cineole. In particular, α-pinene, α-~~  
34  
35 390 ~~terpineol, terpinen-4-ol and p-cymene, detected in considerable amount in *O. quixos*~~  
36  
37 391 ~~EO, revealed a high antiviral activity and could be responsible for inactivation action.~~  
38  
39 392 ~~However, in our research, further investigation is required to better elucidate the active~~  
40  
41 393 ~~components and their mixture responsible of the inhibitory effect on virions.~~

42  
43  
44  
45  
46 394

## 47 395 **Results and Discussion**

48  
49 396 The limited efficacy of the current treatment of WNV infection enhances the need for  
50  
51 397 novel therapies that include substances with innovative viral targets and/or mechanisms  
52  
53 398 of action. So far, only a limited number of plant-derived products are effective against  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 399 viruses, which has prompted research into finding new antiviral lead molecules  
4  
5 400 (Lohézic-Le Dévéhat et al. 2002; Schnitzler et al. 2007; Astani et al. 2010; Ocazionez et  
6  
7 401 al. 2010; Elizaquível et al. 2013; Li et al. 2013; Swamy et al. 2016; Tanu and Harper  
8  
9 402 2016).

10  
11 403 Our study has been performed to analyze the potential capacity of *O. quixos* and *P.*  
12  
13 404 *aduncum* EOs, collected in the Ecuadorian Amazon, to reduce the WNV replication in  
14  
15 405 infected cells. *O. quixos* EO was characterized and tested for its antimicrobial,  
16  
17 406 antiplatelet and antithrombotic activity (Naranjo 1981; Sacchetti et al. 2006; Tognolini  
18  
19 407 et al. 2006; Ballabeni et al. 2007; Rolli et al. 2014); from our knowledge no antiviral  
20  
21 408 activities test were performed until now. *P. aduncum* EO has been investigated by  
22  
23 409 several authors mainly focusing on chemical characterization, antimicrobial,  
24  
25 410 insecticidal, larvicidal and anti-protozoic activities (Guerrini et al. 2009; Ling et al.  
26  
27 411 2009; Oliveira et al. 2013; Bernuci et al. 2016; Monzote et al. 2017; Villamizar et al.  
28  
29 412 2017). In addition, *P. aduncum* was found active on Poliovirus (Lohézic-Le Dévéhat et  
30  
31 413 al. 2002).

32  
33  
34  
35 414 In the present work the chemical composition of *O. quixos* and *P. aduncum* EOs was  
36  
37 415 determined by GC-MS and GC-FID. The yield of distillation for *O. quixos* EO was  
38  
39 416  $0.13\pm 0.01\%$  (w/v), comparable with our previous results (Sacchetti et al. 2006). The  
40  
41 417 main component was represented by 1,8-cineole (39.15%), followed in less amount by  
42  
43 418  $\alpha$ -terpineol (7.65%), sabinene (6.46%),  $\alpha$ -pinene (6.27%), p-cymene (6.12%), E-  
44  
45 419 caryophyllene (4.73%), terpinen-4-ol (4.22%) (Table 1): monoterpenes were therefore  
46  
47 420 the main fraction of EO. This chemical profile did not reflect our previous data  
48  
49 421 (Sacchetti et al. 2006), where E-caryophyllene, cinnamyl acetate and other derivatives  
50  
51 422 were the characteristic molecules. Moreover, methyl cinnamate, a typical  
52  
53 423 phenylpropanoid of floral calyx EO (Bruni et al. 2004), was a minor compound derived  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 424 from leaves (1.53%). The chemical characterization of leaf EO has not been studied  
4  
5 425 extensively in literature  date. However, it can be highlighted that  biodiversity of  
6  
7 426  Amazonian region can induce plant secondary metabolism to biosynthetic pathways  
8  
9 427 characterized by diversified molecules  that can justify the different chemical profile of  
10  
11 428 EOs derived by  the same species  (Calvenzi et al., 2017).

12  
13 429 Regarding *P. aduncum* EO, the data were similar to those previously published  
14  
15 430 (Guerrini et al. 2009) with  phenylpropanoid  dillapiole (48.21%), *trans*-ocimene (7.53%)  
16  
17 431 and E-caryophyllene (4.80%) as main compounds and small quantitative differences on  
18  
19 432 minor compounds and germacrene D (3.05%) that was not detected in the past research.  
20  
21 433 The yield was 0.16±0.01% (w/v). *P. aduncum* EO have been largely studied in literature  
22  
23 434 in the last two decades and the formation of two chemotypes by different biosynthetic  
24  
25 435 routes has been evidenced. In fact, according to our data, different studies on EOs ~~from~~  
26  
27 436 ~~leaves of~~ *P. aduncum* leaf OEs, “derived from different localities of Amazonian  
28  
29 437 region”, showed that dillapiole, formed by the shikimate pathway, was the main  
30  
31 438 compound with a variability from 31.5% to 97.3%, (Ciccio and Ballester 1997, Maia et  
32  
33 439 al. 1998, Fazolin et al. 2007 and De Almeida et al. 2009). In addition, the study of *P.*  
34  
35 440 *aduncum* cultivation in Western Amazonian region confirmed dillapiole as major  
36  
37 441 component (Silva et al. 2014). If the leaves were instead collected from species in  
38  
39 442  Atlantic Forest, ~~and~~ Northeastern and Southeastern  Brazil, terpene compounds such as  
40  
41 443 (E)-nerolidol and linalool were detected as main components (De Oliveira et al. 2006;  
42  
43 444 Debonsi Navickiene et al. 2006; De Almeida et al. 2009). The yield of dillapiole-  
44  
45 445 chemotype EO in literature  ranged from 0.35% to 4.0% (Fazolin et al. 2007; Rali et al.  
46  
47 446 2007; De Almeida et al. 2009; Guerrini et al. 2009; Silva et al. 2014), our results instead  
48  
49 447 showed a lower level (0.16%).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 448 EOs were tested for their cytotoxicity on Vero cells prior to the determination of their  
4  
5 449 inhibitory effect against WNV, by using a neutral red assay in which the half maximal  
6  
7 450 cytotoxic concentration (CC<sub>50</sub>) value of each compound was calculated. *P. aduncum*  
8  
9 451 resulted relatively more toxic than *O. quixos*. Indeed, the results illustrated a CC<sub>50</sub> value  
10  
11 452 of 163 µg/mL for *P. aduncum* and 840 µg/mL for *O. quixos*. Treated cells with vehicle  
12  
13 453 control, 1% DMSO, did not show any cytotoxicity against Vero cells (Table 2).

14  
15 454 In order to evaluate the effect of *O. quixos* and *P. aduncum* on viral replication, Vero  
16  
17 455 cells were infected with WNV at 0.1 m.o.i. p.f.u./cell and exposed to various two-fold  
18  
19 456 concentrations of EO starting from 2.6 µg/mL for 72 h post-infection (p.i.).

20  
21 457 Results are presented in Figure 1 as percentage of cell viability and represent the  
22  
23 458 average of three independent experiments. As shown in the figure, both EOs were able  
24  
25 459 to inhibit viral replication but *O. quixos* was more effective at concentration of 268 and  
26  
27 460 134.4 µg/mL respect *P. aduncum* that showed a viral inhibition similar for all  
28  
29 461 concentrations. The 50% effective concentration (EC<sub>50</sub>) for *O. quixos* was 372 µg/mL  
30  
31 462 while selectivity index (SI) of 2.2 (Table 2).




32  
33 463 In order to better investigate the inhibitory effects of *O. quixos* and *P. aduncum* on  
34  
35 464 WNV, EOs was added at different stages during viral infection. As shown on Figure 2,  
36  
37 465 no relevant differences between the antiviral activities of *O. quixos* OE were  
38  
39 466 observed in all conditions studied. The highest percentages of cell viability (>60%)  
40  
41 467 were observed when the EO was added to the host cells at the concentrations of 16.8  
42  
43 468 and 33.6 µg/mL prior to the infection. Similar results were obtained when 33.6 µg/mL  
44  
45 469 of EO were added during the adsorption step. Differently, when the EO was added at  
46  
47 470 low concentrations (1 and 2.1 µg/mL) no relevant antiviral activity was observed in any  
48  
49 471 conditions.


1  
2  
3 472 Antiviral activity of the *P. aduncum* was most pronounced when the virus was treated  
4  
5 473 before inoculation (Figure 3A) showing a percentage of cell viability of 79% at the  
6  
7 474 concentrations of 33.6  $\mu\text{g/mL}$ , 88% at 16.8  $\mu\text{g/mL}$ , 87% and 78% at 2.1 and 1  $\mu\text{g/mL}$ ,  
8  
9 475 respectively. When cells were incubated with EO only 1  $\mu\text{g/mL}$  showed protection  
10  
11 476 (68% of cell viability) while no relevant antiviral activity was shown by the other  
12  
13 477 concentrations (Figure 3(B)). When the EO was added during infection, the results  
14  
15 478 showed an antiviral activity at all the concentrations with a percentage of cell viability  
16  
17 479 of around 68% at 1  $\mu\text{g/mL}$  (Figure 3 (C)).


18  
19 480 Results of the present paper showed that the antiviral activity of *P. aduncum* EO had  
20  
21 481 mainly virucidal activity. In literature there aren't many studies of virucidal effect of  
22  
23 482 EOs on WNV. Experiments aimed to assess the antiviral activity of EOs have been most  
24  
25 483 frequently conducted on viruses of the herpes group, enveloped viruses (Novak 2011).  
26  
27 484 Schnitzler et al. (2007) demonstrated a virucidal effect of peppermint oil, when herpes  
28  
29 485 simplex virus was mixed with the EO prior to inoculation. The application of tea tree  
30  
31 486 oil, the EO of *Melaleuca alternifolia*, for the treatment of recurrent herpes labialis has  
32  
33 487 been recently reported (Carson et al. 2001; Schuhmacher et al. 2003). Concerning  
34  
35 488 antiviral activity on others members of the Flaviviridae family, many studies with  
36  
37 489 dengue virus (DENV) have been reported (Garcia et al. 2003; Duschatzky et al. 2005;  
38  
39 490 Raquel Elvira Ocazonez et al 2010; Klawikkan 2011). These latter data support the  
40  
41 491 hypothesis that *P. aduncum* EO components may directly contribute to the inactivation  
42  
43 492 of viral particles by interfering with envelope or masking viral glycoproteins that are  
44  
45 493 necessary for entering host cells.



46  
47 494 Accordingly, a virus lacking of envelope, like adenovirus, was not affected by  
48  
49 495 *Eucalyptus* EO (Cermelli et al. 2008). Therefore our results suggest that *O. quixos* and  
50  
51 496 *P. aduncum* could directly inactivate WNV and might interfere with virion envelope  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 497 structures or mask viral structures which are necessary for adsorption or entry into host  
4  
5 498 cells.

6  
7 499 In this study, experiments were also performed to determine the viral inhibitory effect  
8  
9 500 ating the cells with EOs before adsorption. This different approach was important to  
10  
11 501 better investigate of mechanisms of antiviral action of the EOs. In our study, *O. quixos*  
12  
13 502 showed a protection of the cells from viral infection unlike  *aduncum*.



14  
15 503 Previous studies with EOs from eucalyptus, tea tree and thyme have shown the direct  
16  
17 504 inactivating action of EOs and their components on virion infectivity (HSV-1), with the  
18  
19 505 exception of 1,8-cineole (Astani et al. 2010). Although 1,8-cineole was the main  
20  
21 506 component of *O. quixos*, our results showed a good antiviral effect of this EO. In  
22  
23 507 particular, Astani et al. onstrated that  $\alpha$ -pinene,  $\alpha$ -terpineol, terpinen-4-ol and p-  
24  
25 508 cymene, components detected also in *O. quixos* EO, revealed a high antiviral activity  
26  
27 509 and could be responsible for inactivation action. These data highlight the need to  
28  
29 510 analyze the efficacy of the single components of *O. quixos* EO in further studies.

30  
31 511 For *O. quixos* we observed a good and similar protection from WNV infection ding  
32  
33 512 the EO to the DMEM medium during the intracellular replication period, up to an EO  
34  
35 513 concentration of 16.8  $\mu\text{g/mL}$ . These results suggest that *O. quixos* could act directly on  
36  
37 514 WNV virus and might interfere with virion envelope structures or mask viral structures,  
38  
39 515 which are necessary for adsorption or entry into host cells. Thus different mechanisms  
40  
41 516 of antiviral activity of different EOs and compounds seem to be present.

42  
43 517 *P. aduncum* didn't result ective when added to the cells before inoculation n this  
44  
45 518 case we might, in some ways, assume that the oil does not act by competing with the  
46  
47 519 virus for binding to the cell, and that part of its activity relies on direct inactivation of  
48  
49 520 the viral particles after virus adsorption.

1  
2  
3 521 All together, these results support the potential use of EOs in toto from medicinal plants  
4  
5 522 as agents for the treatment of viral infections. The effectiveness of the EOs from  
6  
7 523 Amazonia against the viruses tested was variable, but their virucidal properties against  
8  
9 524 these viruses suggest the application of this type of natural products as disinfectants or  
10  
11 525 topical medicaments.



12  
13 526 However, in our research  further investigation is required to better elucidate the active  
14  
15 527 components and their mixture responsible  the inhibitory effect on virions.

16  
17 528 Viral diseases are still a major problem for human health worldwide. Although   
18  
19 529 intrinsic complexity of natural products, the research trend  clearly indicate that plant-  
20  
21 530 based products will be among the most important sources of new drugs in the future  
22  
23 531 (Atanasov et al. 2015).

24  
25  
26 532

27  
28  
29 533

### 30 31 534 **Acknowledgements**

32  
33 535 This research has been supported by grant  from the Universidad Estatal Amazónica,  
34  
35 536 Ecuador, the University of Ferrara, Italy (FAR 2016-Guerrini) and the National  
36  
37 537 Reference Laboratory for Arboviruses, Istituto Superiore di Sanità. The accomplishment  
38  
39 538 of the present article is framed in the activities  the agreement MAE-DNB-CM-2015-  
40  
41 539 0027 in force between the Ministry of the Environment of Ecuador and the State  
42  
43 540 University Amazon.

44  
45  
46 541

### 47 48 49 542 **Statistical analysis**

50  
51  
52 543 ~~The experiments were performed in triplicate and were determined by logarithmic~~  
53  
54 544 ~~regression curves with 95% confident limits. Relative standard deviations and statistical~~

1  
2  
3 545 ~~significance (Student's t test;  $p \leq 0.05$ ) were calculated using software STATISTICA~~  
4  
5 546 ~~6.0 (StatSoft Italia srl)~~  
6

7 547  
8  
9

10 548 **References**

11  
12  
13 549 Adams RP. 2007. Identification of Essential Oil Components by Gas  
14  
15 550 Chromatography/Masspectrometry, 4th ed. Carol Stream (IL): Allured Publishing Co

16  
17  
18 551 Astani A, Reichling J, Schnitzler P. 2010. Comparative Study on the Antiviral Activity of  
19  
20 552 Selected Monoterpenes Derived from Essential Oils. *Phytother- Res.* (24):673–679.

21  
22  
23 553 Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P,  
24  
25 554 Temml V, Wang L, Schwaiger S, Heiss EH. 2015. Discovery and resupply of  
26  
27 555 pharmacologically active plant-derived natural products: A review. *Biotechnol- Adv.*  
28  
29 556 (33):1582-1614.

30  
31 557 Ballabeni V, Tognolini M, Bertoni S, Bruni R, Guerrini A, Moreno Rueda G, Barocelli E.  
32  
33 558 2007. Antiplatelet and antithrombotic activities of essential oil from wild *Ocotea quixos*  
34  
35 559 (*Lam.*) ~~K~~Kosterm (*Lauraceae*) calices from amazonian Ecuador. *Pharmacol- Res.* (55):23-  
36  
37 560 30.

38  
39  
40 561 Bernuci ZK, Iwanaga CC, Fernandez-Andrade CMM, Brusco Lorenzetti F, Caio Torres-  
42  
43 562 Santos E, dos Santos Faiões V, Gonçalves JE, do Amaral W, Deschamps C, de Lima Scodro  
44  
45 563 R, Fressatti Cardoso R, Vanessa PietrowskiBaldin V, Garcia Cortez DA. 2016. Evaluation  
46  
47 564 of Chemical Composition and Antileishmanial and Antituberculosis Activities of Essential  
48  
49 565 Oils of Piper Species. *Molecules.* (21):1698.

50  
51 566 Bhalla Y, Gupta VK, Jaitak V. 2013. Anticancer activity of essential oil: A review. *J- Sci-*  
52  
53 567 *Food Agric.* (93):3643–3653.  
54  
55  
56  
57



- 1  
2  
3 568 Bruni R, Medici A, Andreotti E, Fantin C, Muzzoli M, Dehesa M, Romagnoli C, Sacchetti  
4  
5 569 G. 2004. Chemical composition and biological activities of ishingpo essential oil, a  
6  
7 570 traditional ecuadorian spice from *Ocotea quixos* (Lam.) Kosterm. (Lauraceae) flower  
8  
9 571 calices. Food Chem. (85):415-421.
- 10  
11 572 Carson CF, Ashton L, Dry L, Smith DW, Riley TV. 2001. *Melaleuca alternifolia* (tea tree)  
12  
13 573 oil gel (6%) for the treatment of recurrent herpes labialis. J Antimicrob Chemother. (48):  
14  
15 574 450–451.
- 16  
17  
18 575 Ciccio JF, Ballesteros CM. 1997. Constituyentes volátiles de las hojas y espigas de *Piper*  
19  
20 576 *aduncum* (Piperaceae) de Costa Rica. Rev Biol Trop. 45(2):783-790.
- 21  
22  
23 577 Cermelli C, Fabio A, Fabio G, Quaglio P. 2008. Effect of Eucalyptus Essential Oil on  
24  
25 578 Respiratory Bacteria and Viruses. CurrMicrobiol. 56(1):89-92.
- 26  
27  
28 579 David S, Abraham AM. 2016. Epidemiological and clinical aspects on West Nile virus, a  
29  
30 580 globally emerging pathogen. Infect Dis (Lond). 48(8):571-86.
- 31  
32  
33 581 De Almeida RRP, Souto RNP, Bastos CN, Da Silva MHL, Maia JGS. 2009. Chemical  
34  
35 582 variation in *Piper aduncum* and biological properties of its dillapiole-rich essential oil.  
36  
37 583 ChemBiodivers. 6(9):1427-1434.
- 38  
39  
40 584 **Deboni Navickiene HM, Morandim ADA, Alécio AC, Regasini LO, Bergamo DCB,**  
41  
42 585 **Telascrea M, Cavalheiro AJ, Lopes MN, Bolzani VDS, Furlan M, Marques MOM, Young**  
43  
44 586 **MCM, Kato MJ. 2006. Composition and antifungal activity of essential oils from *Piper***  
45  
46 587 ***aduncum*, *Piper arboreum* and *Piper tuberculatum*. Quím. Nova. 29(3):467-470.**
- 47  
48  
49 588 De Oliveira JCS, Dias IJM, Da Camara CAG. 2006. Volatile Constituents of the Leaf Oils  
50  
51 589 of *Piper aduncum* L. from Different Regions of Pernambuco (Northeast of Brazil). J **Essent**  
52  
53 590 **Oil Res**~~ESSENT OIL RES~~. 18(5):557-559.
- 54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 591 Durant-Archibold AA, Santana AI, Gupta PM. 2018. Ethnomedical uses and  
4 592 pharmacological activities of most prevalent species of genus *Piper* in Panama: A review.  
5 593 *Journal of Ethnopharmacol.* (217): 63–82  
6  
7  
8  
9 594 Elizaquível P, Azizkhani M, Aznar R, Sánchez G. 2013. The effect of essential oils on  
10 595 norovirus surrogates. *Food Control.* (32):275-278.  
11  
12  
13  
14 596 Fazolin M, Estrela JLV, Catani V, Alécio MR, de Lima MS. 2007. Insecticidal properties of  
15 597 essential oils of *Piper hispidinervum* C. DC.; *Piper aduncum* L. and *Tanaeciumnocturnum*  
16 598 (Barb. Rodr.) Bur. & K. Shum against *Tenebrio molitor* L. *Ciênc- agrotec.* 31 (1):113-120  
17  
18  
19  
20  
21 599 Fortuna C, Remoli ME, Di Luca M, Severini F, Toma L, Benedetti E, Bucci P, Montarsi F,  
22 600 Minelli G, Boccolini D, Romi R, Ciufolini MG. 2015. Experimental studies on comparison  
23 601 of the vector competence of four Italian *Culex pipiens* populations for West Nile  
24 602 virus. *Parasit Vectors.* (8):463.  
25  
26  
27  
28  
29  
30 603 Friedman J, Bolotin D, Rios M, Mendosa P, Cohen Y, Balick M.J. 1993. A novel method  
31 604 for identification and domestication of indigenous useful plants in Amazonian Ecuador.  
32 605 *New crops.* 167-174.  
33  
34  
35  
36  
37 606 García, CC, Talarico L, Almeida N, Colombres S, Duschatzky C and Damonte EB. 2003.  
38 607 Virucidal activity of essential oils from aromatic plants of San Luis, Argentina. *Phytother*  
39 608 *Res.* 17:1073-1075.  
40  
41  
42  
43  
44 609 Gubler DJ. 2007. The continuing spread of West Nile virus in the western hemisphere. *Clin-*  
45 610 *InfectDis.* 45(8):1039–1046.  
46  
47  
48  
49 611 Guerrini A, Rossi D, Grandini A, Scalvenzi L, Noriega Rivera PF, Andreotti E, Tacchini M,  
50 612 Spagnoletti A, Poppi I, Maietti S. 2014. Biological and chemo-diverse characterization of  
51 613 Amazonian (Ecuador) *Citrus* petigrains. *J Appl Bot Food Qual.* (87):108–116.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 614 Guerrini A, Sacchetti G, Rossi D, Paganetto G, Muzzoli M, Andreotti E, Tognolini M,  
4 615 Maldonado ME, Bruni R. 2009. Bioactivities of *Piper aduncum* L. and *Piper obliquum* Ruiz  
5 & Pavon (Piperaceae) essential oils from Eastern Ecuador. *Environ Toxicol Pharmacol.*  
6 616 *27(1):39-48.*  
7  
8  
9 617  
10  
11 618 Li D, Baert L, Uyttendaele M. 2013. Inactivation of food-borne viruses using natural  
12  
13 619 biochemical substances. *Food Microbiol.* (35):1-9.  
14  
15  
16 620 Ling A I, Sulaiman S, Othman H. 2009. Evaluation of *Piper aduncum* Linn. Essential Oil  
17  
18 621 (Fam:Piperaceae) against *Periplaneta americana* (L.). *Iranian J Arthropod-Borne Dis.* 3(2):  
19  
20 622 1-6.  
21  
22  
23 623 Lohézic-Le Dévéhat F, Bakhtiar A, Bézivin C, Amoros M, Boustie J. 2002. Antiviral and  
24  
25 624 cytotoxicactivities of some Indonesianplants. *Fitoterapia.* (73):400-405.  
26  
27  
28 625 Magurano F, Remoli ME, Baggieri M, Fortuna C, Marchi A, Fiorentini C, Bucci P,  
29  
30 626 Benedetti E, Ciufolini MG, Rizzo C, Piga S, Salcuni P, Rezza G, Nicoletti L. 2012.  
31  
32 627 Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy. *ClinMicrobiol*  
33  
34 628 *Infect.* (12) 545-547.  
35  
36  
37 629 Maia, JGS, Zohhbi MDGB, Andrade EHA, Santos AS, Da Silva MHL, Luz AIR, Bastos  
38  
39 630 CN. 1998. Constituents of the essential oil of *Piper aduncum* L. growing wild in the  
40  
41 631 Amazon region. *Flavour Fragr- J.* 13(4):269-272.  
42  
43  
44 632 Mamood SN, Hidayatulfathi O, Budin SB, Ahmad Rohi G, Zulfakar MH. 2017. The  
45  
46 633 formulation of the essential oil of *Piper aduncum* Linnaeus (Piperales: Piperaceae) increases  
47  
48 634 its efficacy as an insect repellent. *Bull Entomol Res.* (1):49-57.  
49  
50  
51 635 Mittermeier RA, Mittermeier CG, Gil PR. 1999. Megadiversity: Earth's biologically  
52  
53 636 wealthiest nations. *Chelonian Conserv. Biol.* (3):537-537.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 637 Monzote L, Scull R, Cos P, Setzer WN. 2017. Essential Oil from *Piper aduncum*: Chemical  
4 638 Analysis, Antimicrobial Assessment, and Literature Review. *Medicines*. 4(49).  
5  
6  
7 639 Naranjo P. 1981. *Ocotea quixos*, American cinnamon. *J. Ethnopharmacol.* (4):233 – 236.  
8  
9  
10 640 Newman DJ, Cragg GM. 2007. Natural products as sources of new drugs over the last 25  
11 641 years. *J. Nat. Prod.* (70):461-477.  
12  
13  
14  
15 642 Nowak A. 2011. The inhibitory effect of essential oil on HSV-1 and HSV-2 virus. *Post*  
16 643 *Fitoter.* (4):243–247.  
17  
18  
19  
20 644 Ocazonez RE, Meneses R, Torres FA, Stashenko E. 2010. Virucidal activity of Colombian  
21 645 Lippia essential oils on dengue virus replication *in vitro*. *Mem Inst Oswaldo Cruz, Rio de*  
22 646 *Janeiro.* 105(3):304-309.  
23  
24  
25  
26  
27 647 Oliveira GL, Cardoso SK, Lara Júnior CR, Vieira TM, Guimães EF, Figueiredo LS, Martins  
28 648 ER, Moreira DL, Kaplan MAC. 2013. Chemical study and larvicidal activity against  
29 649 *Aedes aegypti* of essential oil of *Piper aduncum* L. (Piperaceae). *An Acad Bras Cienc.* 85(4).  
30  
31  
32  
33  
34 650 Pietrantoni A, Fortuna C, Remoli ME, Ciufolini MG, Superti F. 2015. Bovine lactoferrin  
35 651 inhibits Toscana virus infection by binding to heparan sulphate. *Viruses.* Jan-29;7(2):480-  
36 652 495.  
37  
38  
39  
40  
41 653 Rali T, Wossa SW, Leach DN, Waterman PG. 2007. Volatile chemical constituents of *Piper*  
42 654 *aduncum* L and *Piper gibbilimum* C. DC (Piperaceae) from Papua New Guinea. *Molecules.*  
43 655 12(3):389-394.  
44  
45  
46  
47  
48 656 Rolli E, Marieschi M, Maietti S, Sacchetti G, Bruni R. 2014. Comparative phytotoxicity of  
49 657 25 essential oils on pre- and post-emergence development of *solanum lycopersicum* l.: A  
50 658 multivariate approach. *Ind Crops Prod.* (60):280-290.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 659 Sacchetti G, Guerrini A, Noriega P, Bianchi A, Bruni R. 2006. Essential oil of wild  
4  
5 660 *Ocoteaquixos* (Lam.) Kosterm. (Lauraceae) leaves from amazonian Ecuador. *FlavourFragr-*  
6  
7 661 *J.* (21):674-676.
- 8  
9  
10 662 Saxena V, Bolling BG, Wang T. 2017. West Nile Virus. *Clin Lab Med.* ~~Jun~~;37(2):243-252.
- 11  
12 663 Scalvenzi L, Grandini A, Spagnoletti A, Tacchini M, Neill D, Ballesteros JL, Sacchetti G,  
13  
14 664 ~~S~~-Guerrini A. 2017. *Myrciasplendens* (Sw.) DC. (syn. *M. fallax* (Rich.) DC.) (Myrtaceae)  
15  
16 665 essential oil from Amazonian Ecuador: A chemical characterization and bioactive profile.  
17  
18 666 *Molecules.* ~~(22)~~(7):E1163.
- 19  
20  
21 667 Schnitzler P, Koch C, Reichling J. 2007. Susceptibility of Drug-Resistant Clinical Herpes  
22  
23 668 Simplex Virus Type 1 Strains to Essential Oils of Ginger, Thyme, Hyssop, and  
24  
25 669 Sandalwood. *Antimicrob- Agents Chemother.* ~~May~~51(5):1859–1862.
- 26  
27  
28 670 Schuhmacher J, Reichling J, P. Schnitzler P. 2003. Virucidal effect of peppermint oil on the  
29  
30 671 enveloped viruses herpes simplex virus type 1 and type 2 *in vitro*. *Phytomedicine.* ~~(10)~~(6-  
31  
32 672 ~~7~~):504–510.
- 33  
34  
35 673 Sierra R, Campos F, Chamberlin J. 2002. Assessing biodiversity conservation priorities:  
36  
37 674 Ecosystem risk and representativeness in continental Ecuador. *Landsc Urban Plan. Int- J-*  
38  
39 675 *Geogr. Inf. Sci.* ~~(59)~~(2):95-110.
- 40  
41  
42 676 Silva AL, Chaves FCM, Lameira RC, Bizzo HR. 2014. Yield and composition of the  
43  
44 677 essential oil from *Piper aduncum* L., cultivated in Manaus, AM, regarding plant density and  
45  
46 678 cutting period. *Rev- bBras- pPlantas mMed.* 15(4)(SUPPLSuppl1):670-674.
- 47  
48  
49 679 Swamy MK, Akhtar MS, Sinniah UR. 2016. Antimicrobial Properties of Plant Essential  
50  
51 680 Oils against Human Pathogens and Their Mode of Action: An Updated Review. *Evid-*  
52  
53 681 *Based Complement- Alternat- Med.* ~~Article~~ ID ~~3012462~~; ~~21~~  
54  
55 682 ~~pages~~<http://dx.doi.org/10.1155/2016/3012462>

- 1  
2  
3 683 Tanu B, Harpreet K. 2016. Benefits of essential oil. J Chem Pharm Res. 8(6):143-149.  
4  
5  
6 684 Tognolini M, Barocelli E, Ballabeni V, Bruni R, Bianchi A, Chiavarini M, Impicciatore M.  
7  
8 685 2006. Comparative screening of plant essential oils: Phenylpropanoid moiety as basic core  
9  
10 686 for antiplatelet activity. Life Sciences. (78):1419-1432.  
11  
12 687 Vázquez-Calvo Á, Jiménez de Oya N, Martín-Acebes MA, Garcia-Moruno E, Saiz JC.  
13  
14 688 2017. Antiviral Properties of the Natural Polyphenols Delphinidin and Epigallocatechin  
15  
16 689 Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front  
17  
18 690 Microbiol. 8:1314.  
19  
20  
21 691 Villamizar LH, Cardoso MDG, de Andrade J, Teixeira ML, Soares MJ. 2017. Linalool, a  
22  
23 692 *Piper aduncum* essential oil component, has selective activity against *Trypanosoma cruzi*  
24  
25 693 *trypomastigote* forms at 4°C. Mem Inst Oswaldo Cruz, Rio de Janeiro. 112(2):131-139.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Antiviral activity of *O. quixos* (◆) and *P. aduncum* (■) against WNV during intracellular virus replication. Results are presented as mean of three independent experiments  $\pm$  SD ( $p < 0.05$ )




Figure 2. Antiviral activity of *O. quixos* against WNV at 0.1 m.o.i.p.f.u./cell (A) after incubation of virus with different concentrations of EO 1h at 37° C before infection ; (B) after pre-treatment of cells with drugs before viral infection 1h at 37° C (C) after treatment with different concentrations of EO during infection. CC = cell control; CV = virus control






Figure 3. Antiviral activity of *P. aduncum* against WNV at 0.1 m.o.i. p.f.u./cell (A) after incubation of virus with different concentrations of EO 1 h at 37° C before infection; (B) after pre-treatment of cells with drugs before viral infection 1 h at 37° C (C) after treatment with different concentrations of EO during infection. CC = cell control; CV = virus control




Table 1. Chemical composition of *O. quixos* and *P. aduncum* EOs

No.	Component <sup>1</sup>	<i>O. quixos</i> (Area %) <sup>2†</sup>	<i>P. aduncum</i> (Area%) <sup>2†</sup>	RI exp <sup>32</sup>	RI lit <sup>4</sup> lett <sup>3</sup>
1	$\alpha$ -thujene	1.50±0.09	0.23±0.02	922	924
2	<b><math>\alpha</math>-pinene</b>	<b>6.27±0.47</b>	1.63±0.14	929	<b>932</b>
3	camphene	0.16±0.02	-	944	<b>946</b>
4	<b>sabinene</b>	<b>6.46±0.39</b>	-	967	<b>969</b>
5	$\beta$ -pinene	3.45±0.21	0.99±0.08	973	<b>974</b>
6	myrcene	0.83±0.06	0.42±0.03	987	<b>988</b>
7	$\alpha$ -phellandrene	0.31±0.03	0.78±0.05	1005	<b>1002</b>
8	p-mentha-1(7),8-diene	0.48±0.04	0.16±0.01	1006	<b>1005</b>
9	$\alpha$ -terpinene	1.73±0.11	0.63±0.04	1014	<b>1014</b>
10	<b>p-cymene</b>	<b>6.12±0.42</b>	1.48±0.13	1021	<b>1020</b>
11	o-cymene	-	1.21±0.10	1025	<b>1023</b>
12	limonene	1.84±0.11	1.10±0.11	1026	<b>1024</b>
13	<b>1,8-cineole</b>	<b>39.15±2.32</b>	-	1028	<b>1026</b>
14	cis-ocimene	-	3.33±0.27	1032	<b>1032</b>
15	<b>trans-ocimene</b>	-	<b>7.53±0.48</b>	1043	<b>1044</b>
16	$\gamma$ -terpinene	3.05±0.18	1.99±0.16	1053	<b>1054</b>
17	p-mentha-2,4(8)-diene	0.35±0.02	1.27±0.10	1082	<b>1085</b>
18	$\delta$ -terpineol	0.47±0.04	-	1167	<b>1162</b>
19	terpinen-4-ol	4.22±0.25	1.63±0.12	1176	<b>1174</b>
20	<b><math>\alpha</math>-terpineol</b>	<b>7.65±0.51</b>	-	1193	<b>1186</b>
21	piperitone	-	3.78±0.25	1250	<b>1249</b>
22	$\delta$ -elemene	-	0.10±0.01	1337	<b>1335</b>

23	$\alpha$ -cubebene	0.40±0.03	0.18±0.02	1351	<b>1345</b>
24	cyclosativene	-	0.36±0.03	1369	<b>1370</b>
25	$\alpha$ -ylangene	-	0.18±0.01	1371	<b>1373</b>
26	$\alpha$ -copaene	1.44±0.08	1.23±0.11	1376	<b>1374</b>
27	$\beta$ -cubebene	-	0.11±0.01	1387	<b>1387</b>
28	$\beta$ -elemene	-	0.58±0.03	1388	<b>1389</b>
29	<i>trans</i> -methylcinnamate	1.53±0.06	-	1389	<b>1388</b>
30	$\alpha$ -gurjunene	-	0.50±0.02	1398	<b>1409</b>
31	<b>E-caryophyllene</b>	<b>4.73±0.33</b>	<b>4.80±0.35</b>	1410	<b>1416</b>
32	$\alpha$ -santalene	-	0.10±0.01	1414	<b>1417</b>
33	$\beta$ -copaene	-	0.31±0.02	1424	<b>1430</b>
34	$\gamma$ -elemene	-	0.18±0.01	1427	<b>1434</b>
35	aromadendrene	-	0.29±0.02	1432	<b>1439</b>
36	$\alpha$ -humulene	2.96±0.21	1.74±0.16	1451	<b>1452</b>
37	<i>trans</i> -cadina-1(6),4-diene	-	0.17±0.02	1470	<b>1475</b>
38	$\gamma$ -muurolene	-	0.54±0.05	1473	<b>1478</b>
39	germacrene D	-	3.05±0.29	1477	<b>1484</b>
40	$\beta$ -chamigrene	0.13±0.02	-	1480	<b>1480</b>
41	$\beta$ -selinene	2.00±0.18	0.32±0.02	1484	<b>1489</b>
42	$\gamma$ -amorphene	-	0.28±0.02	1487	<b>1495</b>
43	viridifilorene	-	0.52±0.04	1491	<b>1496</b>
44	bicyclogermacrene	0.79±0.06	-	1491	<b>1500</b>
45	$\alpha$ -muurolene	-	0.33±0.03	1495	<b>1500</b>
46	n-pentadecane	-	0.24±0.01	1500	<b>1500</b>

47	(E,E)- $\alpha$ -farnesene	-	0.53 $\pm$ 0.05	1504	<b>1506</b>
48	$\gamma$ -cadinene	-	0.44 $\pm$ 0.04	1509	<b>1513</b>
49	$\delta$ -amorphene	0.43 $\pm$ 0.04	1.39 $\pm$ 0.12	1516	<b>1511</b>
50	myristicin	-	0.64 $\pm$ 0.05	1524	<b>1517</b>
51	<i>trans</i> - $\gamma$ -bisabolene	0.26 $\pm$ 0.02	-	1526	<b>1531</b>
52	<i>trans</i> -cadin-1(2),4-diene	-	0.16 $\pm$ 0.01	1531	<b>1533</b>
53	$\alpha$ -cadinene	-	0.10 $\pm$ 0.01	1535	<b>1537</b>
54	germacrene B	-	0.50 $\pm$ 0.04	1557	<b>1559</b>
55	spathulenol	0.10 $\pm$ 0.01	0.64 $\pm$ 0.04	1577	<b>1577</b>
56	caryophyllene oxide	0.44 $\pm$ 0.03	0.48 $\pm$ 0.03	1581	<b>1582</b>
57	viridiflorol	-	1.13 $\pm$ 0.11	1593	<b>1592</b>
58	humulene epoxide II	0.19 $\pm$ 0.02	0.27 $\pm$ 0.02	1609	<b>1608</b>
59	<b>dillapiole</b>	-	<b>48.21<math>\pm</math>2.65</b>	1622	<b>1622</b>
Total identified		99.42	98.77		

<sup>1</sup>Components are listed in order of elution and their nomenclature is in accordance of the NIST (National Institute of Standards and Technology) library; <sup>2</sup>Relative peak areas  $\pm$  SEM (standard error media), calculated by GC-FID; <sup>3</sup>RI exp: linear retention indices calculated on a Varian VF-5ms column; <sup>4</sup>RI lit: linear retention indices (Adams *et al.* 2007).

Table 2.  $CC_{50}$  = 50% cytotoxic concentration ( $\mu\text{g/mL}$ );  $EC_{50}$  = 50% effective concentration ( $\mu\text{g/mL}$ );  $SI_{50}$  = selectivity index ( $CC_{50}/EC_{50}$ )

	$CC_{50}$	$EC_{50}$	SI
<i>O. quixos</i>	840 $\mu\text{g/mL}$	372 $\mu\text{g/mL}$	2.2
<i>P. aduncum</i>	163 $\mu\text{g/mL}$	163 $\mu\text{g/mL}$	1

For Peer Review Only